Nuacht

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...
Zacks Investment Research on MSN2 lá
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...
PharmExec2 lá
FDA Approves Regeneron, Sanofi’s Dupixent for Bullous Pemphigoid
FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...
Medical Dialogues15 uair an chloig
FDA Approves Dupilumab as First Targeted Treatment for Bullous Pemphigoid
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...
Medical Dialogues2 lá
Sanofi Dupixent gets USFDA nod for bullous pemphigoid treatment in adults
Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...
The American Journal of Managed Care2 lá
FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid
Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...
Stocktwits on MSN2 lá
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...
FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder
Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...
pharmaphorum2 lá
Dupixent is first FDA-approved drug for rare skin disease
IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...
Sanofi (ENXTPA:SAN) Gains FDA Approval For Dupixent To Address Rare Skin Disease
Sanofi (ENXTPA:SAN) experienced a 4% decline over the past week despite a largely unchanged market. The recent events, including the FDA approval of Dupixent for a rare skin condition and the signing ...
The Pharma Letter2 lá
Dupixent now approved in USA for bullous pemphigoid
Further expanding the indications for French pharma major Sanofi’s (Euronext: SAN) mega-blockbuster Dupixent (dupilumab), the ...
BioSpace13 lá
Sanofi, Regeneron Tout Dupixent’s Effectiveness in Patients With Darker Skin Tone
Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...